Genes and pathways driving glioblastomas in humans and murine disease models

Neurosurgical Review
Adrian Merlo

Abstract

Human malignant gliomas arise from neural progenitor cells and/or dedifferentiated astrocytes. By now, they are genetically so well characterized that several murine glioma models have emerged that faithfully reiterate the typical histological features of the disease. In experimental animals, only one or two elements of the growth factor/Ras, PI3K/PTEN/PKB, p53/ARF/HDM2, and p16/Rb/cyclinD/CDK4 pathways are targeted. In human gliomas, many additional genes and pathways are targeted due to a most severe mutator phenotype that leads to the accumulation of countless epigenetic and genetic alterations. Changes that convey a growth advantage are selected for, leading to overgrowth of precursor cell populations with increasingly malignant tumor cell clones. While murine models represent a powerful tool for elucidating the role of genetic pathways, mechanisms of response and resistance to new therapeutic agents might be fundamentally different due to the high degree of genomic instability in the human disease. In fact, little is known about the molecular causes of genomic instability involved in gliomas, except for the rare Turcot's syndrome, O(6)-methylguanine-DNA methyltransferase, and the apurinic/apyrimidinic endonuclease Ape-1. N...Continue Reading

References

Oct 7, 1985·Brain Research·J P BresslerL M Hjelmeland
Mar 30, 1995·The New England Journal of Medicine·S R HamiltonB Tetu
Mar 14, 1995·Proceedings of the National Academy of Sciences of the United States of America·K E Hunter, M E Hatten
Mar 1, 1993·Proceedings of the National Academy of Sciences of the United States of America·H J YehT F Deuel
Mar 14, 1996·The New England Journal of Medicine·A MerloR Scott
Jul 9, 1996·Proceedings of the National Academy of Sciences of the United States of America·J R SilberM S Berger
May 1, 1996·Current Opinion in Oncology·C D James, J J Olson
Oct 23, 1997·Current Opinion in Cell Biology·S M Frisch, E Ruoslahti
Aug 11, 1998·Nature Genetics·A Di CristofanoP P Pandolfi
Aug 26, 1998·International Journal of Radiation Biology·D W ChanJ Allalunis-Turner
Sep 3, 1998·Journal of Neuroscience Research·K Forsberg-NilssonR D McKay
Dec 16, 1998·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·H S FriedmanP L Modrich
Feb 17, 1999·Proceedings of the National Academy of Sciences of the United States of America·K PodsypaninaR Parsons
Mar 11, 1999·Current Opinion in Genetics & Development·P B DennisG Thomas
May 4, 1999·Trends in Cell Biology·T Maehama, J E Dixon
May 11, 1999·European Journal of Human Genetics : EJHG·M R NelenG W Padberg
May 13, 1999·Molecular Neurobiology·G Fulci, E G Van Meir
May 26, 1999·The Journal of Pathology·C Prives, P A Hall
Feb 1, 2000·International Journal of Cancer. Journal International Du Cancer·L UhrbomB Westermark
Feb 19, 2000·Current Opinion in Genetics & Development·C J Sherr, J D Weber
Mar 31, 2000·Nature Medicine·S BenedettiG Finocchiaro
Apr 8, 2000·Current Opinion in Genetics & Development·J Jiricny, M Nyström-Lahti
Apr 27, 2000·Trends in Genetics : TIG·J C Shen, L A Loeb

❮ Previous
Next ❯

Citations

Apr 25, 2007·Oncogene·X MengZ Shen
Jan 17, 2009·Molecular Medicine·Andreas A Argyriou, Haralabos P Kalofonos
Mar 3, 2009·BMC Cancer·Jean-Louis BoulayFrank Hirth
Apr 16, 2009·Cancer Research·Elaine L BearerVittorio Cristini
Aug 6, 2009·BMC Cancer·Jingmei LiuZhiyuan Shen
Oct 14, 2009·PloS One·Serdar KorurMaria Maddalena Lino
Nov 17, 2010·BMC Medicine·Maria Maddalena LinoJean-Louis Boulay
Apr 1, 2004·Expert Opinion on Therapeutic Patents·Manuel Nieto-SampedroAlfonso Fernández-Mayoralas
Dec 20, 2011·British Journal of Neurosurgery·Gina Farias-EisnerE Sander Connolly
Nov 11, 2016·Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine·Zhipeng LinRunzhou Ni
Nov 5, 2016·Expert Opinion on Emerging Drugs·Julie J Miller, Patrick Y Wen
Jul 28, 2004·Neuropharmacology·Guillermo VelascoManuel Guzmán
Jul 8, 2008·Critical Reviews in Oncology/hematology·Andreas A ArgyriouHaralabos P Kalofonos
Oct 28, 2014·Chemical Research in Toxicology·Nicholas J SchaubDiana-Andra Borca-Tasciuc
Aug 19, 2007·The Journal of International Medical Research·J LinM Zhao
Mar 25, 2015·Biomolecules·Natalia FilippovaLouis Burt Nabors
Mar 3, 2004·Nature Reviews. Cancer·Suzanne J Baker, Peter J McKinnon
Feb 16, 2005·Developmental Neuroscience·Khalid ShahXandra O Breakefield
Jun 4, 2008·Upsala Journal of Medical Sciences·Fredrik Johansson Swartling
Dec 16, 2010·Clinical & Translational Oncology : Official Publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico·Mercedes NúñezRogelio González-Sarmiento
Apr 22, 2004·Science's STKE : Signal Transduction Knowledge Environment·Adrian Merlo, Bernhard Bettler
Aug 22, 2017·Biophysics Reviews·Leonardo B de PaulaAntonio C Tedesco
Jan 1, 2014·Zhurnal voprosy neĭrokhirurgii imeni N. N. Burdenko·G V PavlovaA N Konovalov
Apr 14, 2018·BioMed Research International·Fabliha Ahmed ChowdhuryMuhammad Shahdaat Bin Sayeed
Jun 17, 2006·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Stefan KneifelAdrian Merlo
Jan 17, 2009·Cancer Research·Balasubramanian SivasankaranJean-Louis Boulay
Mar 22, 2005·The International Journal of Biochemistry & Cell Biology·Jillian R Gee, Jeffrey N Keller
May 12, 2009·Neurochemistry International·Monika Szeliga, Marta Obara-Michlewska

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cancer Epigenetics & Metabolism (Keystone)

Epigenetic changes are present and dysregulated in many cancers, including DNA methylation, non-coding RNA segments and post-translational protein modifications. The epigenetic changes may or may not provide advantages for the cancer cells. This feed focuses on the relationship between cell metabolism, epigenetics and tumor differentiation.

AKT Pathway

This feed focuses on the AKT serine/threonine kinase, which is an important signaling pathway involved in processes such as glucose metabolism and cell survival.

Cancer Metabolism

In order for cancer cells to maintain rapid, uncontrolled cell proliferation, they must acquire a source of energy. Cancer cells acquire metabolic energy from their surrounding environment and utilize the host cell nutrients to do so. Here is the latest research on cancer metabolism.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Cancer Stem Cells in Glioblastoma

Glioblastoma is the most common and aggressive type of brain tumor. It contains a population of tumor initiating stem cell-like cells known as cancer stem cells. Investigations are ongoing into these cancer stem cells found in these solid tumors which are highly resistance to treatment. Here is the latest research on cancer stem cells in glioblastoma.

Astrocytes

Astrocytes are glial cells that support the blood-brain barrier, facilitate neurotransmission, provide nutrients to neurons, and help repair damaged nervous tissues. Here is the latest research.

Astrocytes & Neurodegeneration

Astrocytes are important for the health and function of the central nervous system. When these cells stop functioning properly, either through gain of function or loss of homeostatic controls, neurodegenerative diseases can occur. Here is the latest research on astrocytes and neurodegeneration.